Surveillance decision

Surveillance decision

We will not update the guideline at this time.

Reason for the decision

We found 25 new studies through surveillance of this guideline.

This included new evidence on access to and the delivery of services and the experience of care, recognition and management of at risk mental states, psychological and psychosocial interventions, and pharmacological interventions that supports current recommendations. We asked topic experts whether this new evidence would affect current recommendations on psychosis and schizophrenia in children and young people. Generally, the topic experts thought that an update was not needed.

We did not find any new evidence related to cognition, employment and education.

None of the new evidence considered in surveillance of this guideline was thought to have an effect on current recommendations.

Other clinical areas

We also found new evidence that was not thought to have an effect on current recommendations. This evidence related to genetic basis of weight gain associated with antipsychotic medications. However, the preliminary nature of the evidence and paucity of further supporting evidence mean it is unlikely to impact the guideline at this time.


No equalities issues were identified during the surveillance process.

Overall decision

After considering all the new evidence and views of topic experts, we decided that an update is not necessary for this guideline.

See how we made the decision for further information.

This page was last updated: 03 November 2016